

Experiment Number: 93020-03
Test Type: 90-DAY
Route: SKIN APPLICATION
Species/Strain: Rat/F 344/N

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Test Compound: Diisopropylcarbodiimide
CAS Number: 693-13-0

Date Report Requested: 10/22/2014
Time Report Requested: 19:31:46
First Dose M/F: NA / NA
Lab: MBA

C Number: C93020
Lock Date: 05/16/1995
Cage Range: All
Date Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: All
Study Gender: Both
PWG Approval Date: NONE

Experiment Number: 93020-03

Test Type: 90-DAY

Route: SKIN APPLICATION

Species/Strain: Rat/F 344/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Test Compound: Diisopropylcarbodiimide

CAS Number: 693-13-0

Date Report Requested: 10/22/2014

Time Report Requested: 19:31:46

First Dose M/F: NA / NA

Lab: MBA

F 344/N Rat MALE	0	MG/KG	10	MG/KG	20	MG/KG	40	MG/KG	80	MG/KG	160	MG/KG
Disposition Summary												
Animals Initially In Study	10		10		10		10		10		10	
Early Deaths												
Moribund Sacrifice									10		3	
Natural Death											7	
Survivors												
Terminal Sacrifice	10		10		10		10					
Animals Examined Microscopically	10		10		10		10		10		10	
ALIMENTARY SYSTEM												
Esophagus	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Large, Cecum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Large, Colon	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Large, Rectum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Duodenum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Ileum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Jejunum	(10)		(0)		(0)		(10)		(10)		(10)	
Liver	(10)		(0)		(0)		(10)		(10)		(10)	
Centrilobular, Congestion									4 [1.5]		6 [2.3]	
Centrilobular, Vacuolization Cytoplasmic									1 [1.0]		6 [1.5]	
Periportal, Vacuolization Cytoplasmic	1 [1.0]											
Pancreas	(10)		(0)		(0)		(10)		(10)		(9)	
Acinus, Atrophy, Focal	1 [1.0]											
Salivary Glands	(10)		(0)		(0)		(10)		(10)		(10)	
Stomach, Forestomach	(10)		(0)		(0)		(10)		(10)		(10)	
Stomach, Glandular	(10)		(0)		(0)		(10)		(10)		(10)	
Cyst									1 [2.0]			
Infiltration Cellular, Mixed Cell									1 [1.0]			
CARDIOVASCULAR SYSTEM												

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-03

Test Type: 90-DAY

Route: SKIN APPLICATION

Species/Strain: Rat/F 344/N

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Test Compound: Diisopropylcarbodiimide

CAS Number: 693-13-0

Date Report Requested: 10/22/2014

Time Report Requested: 19:31:46

First Dose M/F: NA / NA

Lab: MBA

F 344/N Rat MALE	0	MG/KG	10	MG/KG	20	MG/KG	40	MG/KG	80	MG/KG	160	MG/KG
Blood Vessel	(10)		(0)		(0)		(10)		(10)		(10)	
Heart	(10)		(10)		(10)		(10)		(10)		(10)	
Artery, Inflammation, Chronic Active									1 [1.0]			
Cardiomyopathy	4 [1.3]		4 [1.0]		6 [1.0]		4 [1.0]		5 [1.2]		3 [2.7]	
ENDOCRINE SYSTEM												
Adrenal Cortex	(10)		(0)		(0)		(10)		(10)		(10)	
Adrenal Medulla	(10)		(0)		(0)		(10)		(10)		(10)	
Islets, Pancreatic	(10)		(0)		(0)		(10)		(10)		(10)	
Parathyroid Gland	(6)		(0)		(0)		(7)		(9)		(10)	
Pituitary Gland	(10)		(0)		(0)		(10)		(9)		(9)	
Thyroid Gland	(9)		(0)		(0)		(10)		(10)		(10)	
GENERAL BODY SYSTEM												
None												
GENITAL SYSTEM												
Epididymis	(10)		(0)		(0)		(10)		(10)		(10)	
Preputial Gland	(10)		(0)		(0)		(10)		(10)		(10)	
Inflammation, Chronic Active	2 [2.0]						2 [2.5]		1 [2.0]		4 [1.3]	
Prostate	(10)		(0)		(0)		(10)		(10)		(10)	
Seminal Vesicle	(10)		(0)		(0)		(10)		(10)		(10)	
Testes	(10)		(0)		(0)		(10)		(10)		(10)	
HEMATOPOIETIC SYSTEM												
Bone Marrow	(10)		(0)		(0)		(10)		(10)		(10)	
Hemorrhage											2 [2.5]	
Lymph Node, Mandibular	(10)		(0)		(0)		(10)		(10)		(10)	
Hemorrhage							1 [1.0]					
Hyperplasia, Lymphoid	1 [2.0]											
Hyperplasia, Plasma Cell	1 [2.0]											

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-03

Test Type: 90-DAY

Route: SKIN APPLICATION

Species/Strain: Rat/F 344/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Test Compound: Diisopropylcarbodiimide

CAS Number: 693-13-0

Date Report Requested: 10/22/2014

Time Report Requested: 19:31:46

First Dose M/F: NA / NA

Lab: MBA

F 344/N Rat MALE	0	MG/KG	10	MG/KG	20	MG/KG	40	MG/KG	80	MG/KG	160	MG/KG
Lymph Node, Mesenteric	(10)		(0)		(0)		(10)		(10)		(10)	
Necrosis	1	[1.0]										
Spleen	(10)		(10)		(10)		(10)		(10)		(10)	
Lymph Follic, Depletion Cellular											1	[2.0]
Thymus	(10)		(10)		(10)		(10)		(10)		(10)	
Atrophy									2	[2.5]	3	[2.3]
Hemorrhage									2	[2.5]		
Necrosis									2	[2.0]		
INTEGUMENTARY SYSTEM												
Mammary Gland	(10)		(0)		(0)		(9)		(10)		(5)	
Skin	(10)		(10)		(10)		(10)		(10)		(10)	
Epidermis, SOA, Hyperplasia			5	[1.0]	7	[1.0]	10	[1.6]	10	[2.0]	3	[2.3]
Epidermis, SOA, Necrosis, Focal											9	[2.9]
SOA, Inflammation, Chronic Active							1	[1.0]	7	[1.7]	10	[2.8]
MUSCULOSKELETAL SYSTEM												
Bone	(10)		(0)		(0)		(10)		(10)		(10)	
Skeletal Muscle	(9)		(0)		(0)		(10)		(10)		(10)	
NERVOUS SYSTEM												
Brain	(10)		(10)		(10)		(10)		(10)		(10)	
Arteriole, Necrosis, Fibrinoid											1	[1.0]
Congestion											1	[3.0]
Edema, Focal									5	[1.0]	1	[1.0]
Hemorrhage									1	[1.0]	4	[2.3]
Neuron, Necrosis									8	[2.6]		
Peripheral Nerve	(10)		(0)		(0)		(9)		(10)		(10)	
Spinal Cord	(10)		(0)		(0)		(10)		(10)		(10)	
RESPIRATORY SYSTEM												

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-03

Test Type: 90-DAY

Route: SKIN APPLICATION

Species/Strain: Rat/F 344/N

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Test Compound: Diisopropylcarbodiimide

CAS Number: 693-13-0

Date Report Requested: 10/22/2014

Time Report Requested: 19:31:46

First Dose M/F: NA / NA

Lab: MBA

F 344/N Rat MALE	0	MG/KG	10	MG/KG	20	MG/KG	40	MG/KG	80	MG/KG	160	MG/KG
Lung	(10)		(0)		(0)		(10)		(10)		(10)	
Alveolus, Infiltration Cellular, Histiocyte Congestion	1 [1.0]								1 [1.0]		8 [2.8]	
Hemorrhage									1 [2.0]			
Interstitial, Inflammation, Chronic Active	1 [1.0]								1 [2.0]			
Perivascular, Infiltration Cellular, Lymphocyte	3 [1.7]						6 [1.0]		1 [2.0]			
Nose	(10)		(0)		(0)		(10)		(10)		(10)	
Respirat Epith, Inflammation, Chronic Active	3 [1.3]						1 [1.0]		1 [2.0]		5 [1.4]	
Respirat Epith, Metaplasia, Squamous Squam Epithel, Inflammation, Chronic							1 [1.0]				3 [1.7]	
Squam Epithel, Inflammation, Chronic Active											1 [2.0]	
Pleura	(0)		(0)		(0)		(0)		(0)		(1)	
Trachea	(10)		(0)		(0)		(10)		(10)		(10)	
SPECIAL SENSES SYSTEM												
Eye	(0)		(0)		(0)		(0)		(1)		(0)	
Bilateral, Cornea, Degeneration, Focal									1 [2.0]			
Harderian Gland	(0)		(0)		(0)		(0)		(0)		(1)	
URINARY SYSTEM												
Kidney	(10)		(0)		(0)		(10)		(10)		(10)	
Nephropathy	5 [1.0]						2 [1.0]					
Urinary Bladder	(10)		(0)		(0)		(10)		(10)		(10)	

END OF MALE DATA

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-03

Test Type: 90-DAY

Route: SKIN APPLICATION

Species/Strain: Rat/F 344/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Test Compound: Diisopropylcarbodiimide

CAS Number: 693-13-0

Date Report Requested: 10/22/2014

Time Report Requested: 19:31:46

First Dose M/F: NA / NA

Lab: MBA

F 344/N Rat FEMALE	0	MG/KG	10	MG/KG	20	MG/KG	40	MG/KG	80	MG/KG	160	MG/KG
Disposition Summary												
Animals Initially In Study	10		10		10		10		10		10	
Early Deaths												
Moribund Sacrifice									10		10	
Survivors												
Accidentally Killed	1											
Terminal Sacrifice	9		10		10		10					
Animals Examined Microscopically	10		10		10		10		10		10	
ALIMENTARY SYSTEM												
Esophagus	(10)		(0)		(0)		(10)		(9)		(10)	
Intestine Large, Cecum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Large, Colon	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Large, Rectum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Duodenum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Ileum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Jejunum	(10)		(0)		(0)		(10)		(10)		(10)	
Liver	(10)		(0)		(0)		(10)		(10)		(10)	
Centrilobular, Congestion											2 [1.0]	
Congestion									1 [1.0]			
Mesentery	(0)		(0)		(0)		(1)		(0)		(0)	
Fat, Necrosis							1 [3.0]					
Pancreas	(10)		(0)		(0)		(10)		(10)		(10)	
Acinus, Cytoplasmic Alteration, Focal	1 [2.0]											
Salivary Glands	(10)		(0)		(0)		(10)		(10)		(10)	
Stomach, Forestomach	(10)		(0)		(0)		(10)		(10)		(10)	
Stomach, Glandular	(10)		(0)		(0)		(10)		(10)		(10)	
CARDIOVASCULAR SYSTEM												
Blood Vessel	(10)		(0)		(0)		(10)		(10)		(10)	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-03

Test Type: 90-DAY

Route: SKIN APPLICATION

Species/Strain: Rat/F 344/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Test Compound: Diisopropylcarbodiimide

CAS Number: 693-13-0

Date Report Requested: 10/22/2014

Time Report Requested: 19:31:46

First Dose M/F: NA / NA

Lab: MBA

F 344/N Rat FEMALE	0	MG/KG	10	MG/KG	20	MG/KG	40	MG/KG	80	MG/KG	160	MG/KG
Heart	(10)		(10)		(10)		(10)		(10)		(10)	
Cardiomyopathy					1 [1.0]		2 [1.0]		2 [1.0]			
ENDOCRINE SYSTEM												
Adrenal Cortex	(10)		(0)		(0)		(10)		(10)		(10)	
Hypertrophy, Focal	1 [2.0]											
Adrenal Medulla	(9)		(0)		(0)		(10)		(10)		(10)	
Islets, Pancreatic	(10)		(0)		(0)		(10)		(10)		(10)	
Parathyroid Gland	(9)		(0)		(0)		(8)		(9)		(8)	
Pituitary Gland	(10)		(0)		(0)		(9)		(10)		(10)	
Thyroid Gland	(10)		(0)		(0)		(9)		(10)		(10)	
GENERAL BODY SYSTEM												
None												
GENITAL SYSTEM												
Clitoral Gland	(8)		(0)		(0)		(6)		(10)		(10)	
Inflammation, Chronic Active							1 [1.0]		2 [1.0]		1 [1.0]	
Ovary	(10)		(0)		(0)		(10)		(10)		(10)	
Cyst							1 [2.0]					
Uterus	(10)		(1)		(5)		(10)		(10)		(10)	
Hydrometra					5 [3.4]		4 [2.8]				1 [2.0]	
HEMATOPOIETIC SYSTEM												
Bone Marrow	(10)		(0)		(0)		(10)		(10)		(10)	
Atrophy									1 [1.0]			
Hemorrhage									1 [1.0]		2 [2.0]	
Hyperplasia, Histiocytic, Focal							2 [1.5]					
Hyperplasia, Lymphoid, Focal							1 [1.0]					
Lymph Node, Mandibular	(10)		(0)		(0)		(9)		(9)		(10)	
Hemorrhage									1 [2.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-03

Test Type: 90-DAY

Route: SKIN APPLICATION

Species/Strain: Rat/F 344/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Test Compound: Diisopropylcarbodiimide

CAS Number: 693-13-0

Date Report Requested: 10/22/2014

Time Report Requested: 19:31:46

First Dose M/F: NA / NA

Lab: MBA

F 344/N Rat FEMALE	0	MG/KG	10	MG/KG	20	MG/KG	40	MG/KG	80	MG/KG	160	MG/KG
Hyperplasia, Lymphoid Lymph Node, Mesenteric	(10)		(0)		(0)		(10)		1 [2.0]		2 [2.0]	
Hyperplasia, Histiocytic	1 [2.0]						1 [2.0]		(10)		(10)	
Hyperplasia, Lymphoid							1 [3.0]					
Spleen	(10)		(10)		(10)		(10)		(10)		(10)	
Thymus	(10)		(10)		(10)		(10)		(10)		(10)	
Atrophy									4 [2.3]		1 [3.0]	
INTEGUMENTARY SYSTEM												
Mammary Gland	(10)		(0)		(0)		(10)		(9)		(10)	
Skin	(10)		(10)		(10)		(10)		(10)		(10)	
Epidermis, SOA, Hyperplasia	1 [1.0]		2 [1.0]		3 [1.0]		5 [1.0]		10 [1.4]		10 [2.8]	
Epidermis, SOA, Necrosis, Focal											10 [1.6]	
SOA, Inflammation, Chronic Active									7 [1.0]		10 [3.7]	
MUSCULOSKELETAL SYSTEM												
Bone	(10)		(0)		(0)		(10)		(10)		(10)	
Skeletal Muscle	(10)		(0)		(0)		(10)		(10)		(10)	
NERVOUS SYSTEM												
Brain	(10)		(10)		(10)		(10)		(10)		(10)	
Arteriole, Necrosis, Fibrinoid									1 [1.0]			
Edema, Focal									5 [1.0]		2 [1.0]	
Hemorrhage									5 [2.2]		6 [2.0]	
Neuron, Necrosis									8 [2.4]		2 [4.0]	
Peripheral Nerve	(10)		(0)		(0)		(10)		(10)		(10)	
Spinal Cord	(10)		(0)		(0)		(10)		(10)		(10)	
RESPIRATORY SYSTEM												
Lung	(10)		(0)		(0)		(10)		(10)		(10)	
Congestion									5 [1.8]		8 [2.5]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-03

Test Type: 90-DAY

Route: SKIN APPLICATION

Species/Strain: Rat/F 344/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Test Compound: Diisopropylcarbodiimide

CAS Number: 693-13-0

Date Report Requested: 10/22/2014

Time Report Requested: 19:31:46

First Dose M/F: NA / NA

Lab: MBA

F 344/N Rat FEMALE	0	MG/KG	10	MG/KG	20	MG/KG	40	MG/KG	80	MG/KG	160	MG/KG
Hemorrhage									1 [2.0]			
Interstitial, Inflammation, Chronic Active	1 [2.0]						3 [1.7]					
Perivascular, Infiltration Cellular, Lymphocyte	4 [1.3]						5 [2.4]		4 [2.3]			
Nose	(10)		(0)		(0)		(10)		(10)		(10)	
Olfactory Epi, Atrophy	1 [1.0]											
Olfactory Epi, Inflammation, Chronic Active							1 [1.0]					
Respirat Epith, Atrophy									1 [1.0]			
Respirat Epith, Inflammation, Chronic Active	1 [1.0]										2 [1.0]	
Squam Epithel, Inflammation, Chronic Active									1 [1.0]			
Trachea	(10)		(0)		(0)		(10)		(10)		(10)	
SPECIAL SENSES SYSTEM												
None												
URINARY SYSTEM												
Kidney	(10)		(0)		(0)		(10)		(10)		(10)	
Congestion									1 [2.0]		1 [2.0]	
Medulla, Mineralization	5 [1.0]						6 [1.0]		10 [1.0]		3 [1.0]	
Urinary Bladder	(10)		(0)		(0)		(10)		(10)		(10)	
Serosa, Mineralization							1 [2.0]					

** END OF REPORT **

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)